Furthermore, TP53 and CDKN2A mutations in other squamous cell carcinomas such as NSCLC (60) and HNSCC (61) correlates with response to immune checkpoint inhibitors. This evidence concerns the gene TP53 and head and neck squamous cell carcinoma.